Promaxo Announces Research Collaborations with Leading European Universities

Oakland, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) —

Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced it has entered into research collaborations with leading European university hospitals, Imperial College London and University Hospital Tuebingen Germany, for MR guided prostate interventions. In collaboration with Imperial College London, Promaxo is…

expanding its reach into the European market by partnering with prestigious institutions known for their groundbreaking research in the field of medical imaging and robotics. This collaboration will allow Promaxo to leverage the expertise of top researchers and clinicians to further develop and refine its MR guided prostate intervention technology.

Effects on Individuals:

As a result of these research collaborations, individuals may benefit from improved diagnostic and treatment options for prostate conditions. The development of advanced MR guided interventions could lead to more accurate and minimally invasive procedures, ultimately improving patient outcomes and quality of life.

Effects on the World:

The research collaborations between Promaxo and leading European universities have the potential to advance the field of medical imaging and robotics on a global scale. By pushing the boundaries of technology and innovation, these partnerships could drive the development of new medical devices and procedures that benefit patients worldwide.

Conclusion:

The collaboration between Promaxo and Imperial College London, University Hospital Tuebingen Germany, and other leading European universities marks a significant step forward in the field of MR guided prostate interventions. Through these partnerships, Promaxo is poised to make a lasting impact on both individuals and the world at large, driving innovation and improving healthcare outcomes for years to come.